From: Should bioprostheses be considered the valve of choice for dialysis-dependent patients?
Complications | Group B(n = 36) | Group M(n = 33) | P Value |
---|---|---|---|
Valve-related | 6(16.7%) | 11(33.3%) | <0.05 |
Bleeding event | 0 | 2(6.1%) | <0.05 |
Thromboembolism | 0 | 3(9.1%) | <0.05 |
PVE | 2(5.6%) | 2(6.1%) | NS |
Valve deterioration | 0 | 0 | NS |
perivalvular leak | 1(2.8%) | 1(3.0%) | NS |
Reoperation | 3(8.3%) | 3(9.1%) | NS |
Cardiac death | 2 (5.6%) | 2(6.1%) | NS |
Heart failure | 1(2.8%) | 1(3.0%) | NS |
Arrhythmia | 1(2.8%) | 1(3.0%) | NS |
Non-cardiac death | 5(13.9%) | 5(15.2%) | NS |
Malignancy | 3(8.3%) | 2(6.1%) | <0.05 |
Other | 2(5.6%) | 3(9.1%) | <0.05 |
Late mortality | 7(19.4%) | 7(21.2%) | NS |